Alerts will be sent to your verified email
Verify EmailZIMLAB
|
Zim Laboratories
|
Kilitch Drugs(India)
|
Jenburkt Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
6.9 % | n/a | 0.29 % |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 7.31 % | 18.49 % |
|
5yr average Equity Multiplier
|
1.88 | 1.48 | 1.17 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.56 | 0.88 |
|
5yr Avg Net Profit Margin
|
4.15 % | 8.44 % | 18.1 % |
|
Price to Book
|
2.2 | 1.96 | 2.61 |
|
P/E
|
79.4 | 19.95 | 14.81 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 14.76 Days | -32.02 Days |
|
Inventory Days
|
68.72 Days | 14.42 Days | 24.72 Days |
|
Days Receivable
|
99.71 Days | 136.16 Days | 48.38 Days |
|
Days Payable
|
143.26 Days | 212.73 Days | 82.6 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 6.02 | 87.2 |
|
5yr Avg ROCE
|
13.52 % | 11.26 % | 24.44 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 12.28 % | 22.46 % |
|
5 yr average Debt to Equity
|
0.39 | 0.17 | 0.02 |
|
5yr CAGR Net Profit
|
10.7 % | 48.72 % | 14.21 % |
|
5yr Average Return on Assets
|
4.02 % | 4.99 % | 15.8 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
30.35 % | 63.77 % | 46.64 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.91 % | -4.48 % | -0.92 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Zim Laboratories
|
Kilitch Drugs(India)
|
Jenburkt Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|